Skip to main content
Lancet (London, England)
Regional action needed to halt antimalarial drug resistance in Africa.
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
Treatment of fibrotic interstitial lung disease: current approaches and future directions.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Multidrug-resistant tuberculosis - Authors' reply.
Are three drugs for malaria better than two?
Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
A shorter course for anti-relapse therapy against vivax malaria.
Building a tuberculosis-free world: The Lancet Commission on tuberculosis.
